Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate to Severe Chronic Pain Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain

NCT02362672
View directory record Official record
Conditions
Low Back Pain, Chronic Pain
Interventions
NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
54
States / cities
Saraland, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

NCT00490919
View directory record Official record
Conditions
Low Back Pain
Interventions
Buprenorphine transdermal system, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
86
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

NCT01240863
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 9, 2026, 12:17 PM EDT
Withdrawn Not applicable Interventional

Genicular Artery Embolization (GAE) for Osteoarthritic Knee Pain

NCT04472091
View directory record Official record
Conditions
Knee Osteoarthritis, Knee Pain Chronic, Knee Pain Swelling, Knee Arthritis, Arterial Occlusion
Interventions
Genicular artery embolization (GAE)
Device
Lead sponsor
Andrew Picel
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 9, 2026, 12:17 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

NCT03802227
View directory record Official record
Conditions
Moderate to Severe Chronic Pain
Interventions
NKTR-181, Oxycodone IR
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

NCT00376922
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain

NCT02367820
View directory record Official record
Conditions
Low Back Pain, Chronic Pain
Interventions
NKTR-181 BID tablets
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
56
States / cities
Saraland, Alabama • Phoenix, Arizona • Tempe, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 9, 2026, 12:17 PM EDT
Withdrawn Phase 3 Interventional

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain

NCT01431742
View directory record Official record
Conditions
Pain, Low Back Pain
Interventions
BEMA Buprenorphine
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 9, 2026, 12:17 PM EDT
Terminated Phase 2 Interventional

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

NCT00973024
View directory record Official record
Conditions
Low Back Pain, Low Back Pain, Recurrent
Interventions
JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg, JNJ-42160443 10 mg, Matching Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

NCT01115569
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone Bitartrate
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
50
States / cities
Phoenix, Arizona • Sierra Vista, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 9, 2026, 12:17 PM EDT
Terminated Phase 2 Interventional

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

NCT01094262
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis, Knee, Pain, Arthralgia, Joint Pain
Interventions
Oxycodone CR (standard pain medication), JNJ-42160443, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
40 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Carmichael, California • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 2 Interventional

Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain

NCT00485225
View directory record Official record
Conditions
Chronic, Non Malignant Pain
Interventions
EN3270
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

NCT01922739
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 9, 2026, 12:17 PM EDT
Recruiting Phase 2 Interventional

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

NCT05790239
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy
Drug · Behavioral
Lead sponsor
Stephen Robert Marder
Federal
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 9, 2026, 12:17 PM EDT
Terminated Phase 4 Interventional Results available

A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

NCT00381095
View directory record Official record
Conditions
Bone Neoplasms, Pain, Intractable, Cancer
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Celebration, Florida • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

NCT02603705
View directory record Official record
Conditions
Moderate-to-severe Chronic Noncancer Pain
Interventions
Oxycodone extended-release
Drug
Lead sponsor
Egalet Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
39
States / cities
Huntsville, Alabama • Tucson, Arizona • Jacksonville, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain

NCT02620020
View directory record Official record
Conditions
Low Back Pain
Interventions
Fasinumab, placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
58
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 9, 2026, 12:17 PM EDT
Terminated Phase 2 Interventional

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

NCT00278824
View directory record Official record
Conditions
Pain
Interventions
Matrix Transdermal Fentanyl/CHADD Drug Delivery System, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)

NCT01685684
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Oxycodone DETERx, Placebo
Drug
Lead sponsor
Collegium Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee

NCT00531427
View directory record Official record
Conditions
Chronic Pain, Osteoarthritis of the Knee
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
87
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

NCT00929188
View directory record Official record
Conditions
Pain, Burning, Pain, Crushing, Pain, Migratory, Pain, Radiating, Pain, Splitting
Interventions
JNJ-42160443, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Tucson, Arizona • Laguna Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

NCT01789970
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
87
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain

NCT01256450
View directory record Official record
Conditions
Pain, Low Back Pain
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 9, 2026, 12:17 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

NCT03660943
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Placebo, CNTX-4975-05
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 9, 2026, 12:17 PM EDT